



2021 SCIENTIFIC SYMPOSIUM VIRTUAL CONFERENCE March 10-12, 2021

HTRS 2021 Scientific Symposium PRELIMINARY VIRTUAL MEETING AGENDA

<i>HTRS Research Colloquium: March 8-9</i> Agenda: Day 1 Day 2	<i>FWGBD Colloquium: March 9</i> Agenda	<i>Multidisciplinary Pre-Conference: March 10-11</i> Agenda: Day 1 Day 2
<i>HTRS Scientific Symposium: March 10-12</i> Agenda: Day 1 Day 2 Day 3		

MONDAY, MARCH 8, 2021

HTRS Research Colloquium: Day 1 – separate registration required

Eastern Time	Event
12:30 PM – 1:00 PM ET	PRE-MEETING NETWORKING “BRING YOUR OWN LUNCH”
1:00 PM ET	OPENING REMARKS Wolfgang Bergmeier, PhD, and Margaret V. Ragni, MD, MPH, <i>2021 Colloquium Co-Chairs</i>
1:05 PM – 1:50 PM ET	PLENARY SESSION: “HOW DO I BEGIN, AND WHO IS GOING TO PAY FOR THIS?” RESEARCH FUNDING TRENDS AND OPPORTUNITIES <u>Moderator:</u> Margaret V. Ragni, MD, MPH <u>Speaker:</u> Andrei Kindzelski, MD, National Institutes of Health (NIH)
1:50 PM – 2:20 PM ET	NETWORKING BREAK -OR- MENTORING SESSIONS
2:20 PM – 3:20 PM ET	PANEL PRESENTATION: “GETTING A JOB – A RECRUITER’S PERSPECTIVE” <u>Moderator:</u> Wolfgang Bergmeier, PhD
2:20 PM	BASIC SCIENCE PERSPECTIVE James Morrissey, PhD, Professor, University of Michigan
2:35 PM	CLINICAL SCIENCE PERSPECTIVE Janis Abkowitz, PhD, Professor, Hematology Division Head, University of Washington



HTRS Research Colloquium: Day 1 – *continued*

Eastern Time	Event
2:50 PM	TRANSLATIONAL SCIENCE PERSPECTIVE Jorge Di Paola, MD, Professor/Division Chief, Washington University in St. Louis
3:05 PM	INDUSTRY PERSPECTIVE Robert Peters, PhD, Sanofi Genzyme
3:20 PM – 4:00 PM ET	ROUNDTABLE DISCUSSIONS <ul style="list-style-type: none"> • Basic Science Tables • Clinical Science Tables • Translational Science Tables • Population Science Tables
4:00 PM ET	DAY ONE PROGRAM ENDS Session resumes Tuesday, March 9 at 12:30 PM ET

TUESDAY, MARCH 9, 2021

FWGBD Colloquium on Uterine Hemostasis – *separate registration required*

Eastern Time	Event
9:30 AM – 9:45 AM ET	CONVENE AND WELCOME Andra H. James, MD, MPH
9:45 AM – 9:55 AM ET	UTERINE HEMOSTASIS OVERVIEW
9:55 AM – 10:15 AM ET	WOMEN & GIRLS WITH HEMOPHILIA Sarah H. O’Brien, MD, MSc
10:15 AM – 10:30 AM ET	BREAK
10:30 AM – 11:00 AM ET	MANAGEMENT OF DELIVERY IN WOMEN WITH HEMOPHILIA Andra H. James, MD, MPH
11:00 AM – 11:30 AM ET	RISK OF CLOTTING ON HORMONAL THERAPY Naomi Tepper, MD, MPH
11:30 AM – 12:05 PM ET	IS IT HELLP SYNDROME? IS IT TTP? IS IT ATYPICAL HUS? DOES IT MATTER? Gowthami Arepally, MD
12:05 – 12:30 PM ET	DISCUSSION AND WRAP-UP



TUESDAY, MARCH 9, 2021 – *continued*

HTRS Research Colloquium: Day 2 – separate registration required

Eastern Time	Event
12:30 PM – 1:00 PM ET	PRE-MEETING NETWORKING “BRING YOUR OWN LUNCH”
1:00 PM – 1:05 PM ET	DAY TWO - OPENING REMARKS Ming Y. Lim, MD/MBBCH, MSCr, and Joshua Muia, PhD, <i>2021 Colloquium Planning Committee Members</i>
1:05 PM – 1:50 PM ET	PLENARY SESSION: “CRITICAL STEPS FOR A SUCCESSFUL CAREER IN ACADEMIC MEDICINE” <u>Moderator:</u> Mary Cushman, MD, MSc <u>Speaker:</u> Mark T. Gladwin, MD, Jack D. Myers Distinguished Professor and Chair, Chairman of the Department of Medicine, UPMC and the University of Pittsburgh School of Medicine
1:50 PM – 2:10 PM ET	BREAKOUT SESSION 1: “PRACTICAL TOOLS EVERYONE NEEDS TO ADVANCE THEIR CAREERS”
BREAKOUT 1	SPEAK UP: GIVING EFFECTIVE PRESENTATIONS <u>Discussion Leader:</u> Alisa S. Wolberg, PhD
BREAKOUT 2	MANAGING THE K-TO-R TRANSITION: WHAT TO DO IF YOU DON’T GET A K-AWARD <u>Discussion Leader:</u> Nigel Key, MB, ChB, FRCP
BREAKOUT 3	FROM GOOD IDEA TO SUBMITTED GRANT <u>Discussion Leader:</u> Gowthami Arepally, MD
BREAKOUT 4	BEGIN AGAIN: JUMP START YOUR RESEARCH CAREER AFTER A BREAK <u>Discussion Leader:</u> Menaka Pai, BSc, MSc, MD, FRCPC
2:10 PM – 2:30 PM ET	“GET UP AND STRETCH BREAK’ -OR- MENTORING SESSIONS
2:30 PM – 2:50 PM ET	BREAKOUT SESSION 2: “PRACTICAL TOOLS EVERYONE NEEDS TO ADVANCE THEIR CAREERS”
BREAKOUT 1	SPEAK UP: GIVING EFFECTIVE PRESENTATIONS <u>Discussion Leader:</u> Alisa S. Wolberg, PhD
BREAKOUT 2	MANAGING THE K-TO-R TRANSITION: WHAT TO DO IF YOU DON’T GET A K-AWARD <u>Discussion Leader:</u> Nigel Key, MB, ChB, FRCP
BREAKOUT 3	FROM GOOD IDEA TO SUBMITTED GRANT <u>Discussion Leader:</u> Gowthami Arepally, MD
BREAKOUT 4	BEGIN AGAIN: JUMP START YOUR RESEARCH CAREER AFTER A BREAK <u>Discussion Leader:</u> Menaka Pai, BSc, MSc, MD, FRCPC



HTRS Research Colloquium: Day 2 – *continued*

Eastern Time	Event
2:50 PM – 3:35 PM ET	PANEL PRESENTATION: “OVERCOMING OBSTACLES: MOVING YOUR CAREER FORWARD” Moderator: Rodney Camire, PhD
2:50 PM	BASIC/TRANSLATIONAL SCIENCE PERSPECTIVE Veronica H. Flood, MD
3:05 PM	CLINICAL SCIENCE PERSPECTIVE Margaret V. Ragni, MD, MPH
3:20 PM	INDUSTRY PERSPECTIVE Marcus Carr, MD
3:35 PM – 4:20 PM ET	CLOSING RECEPTION “BRNG YOUR OWN SNACKS”
4:20 PM ET	DAY TWO PROGRAM ENDS

WEDNESDAY, MARCH 10, 2021

Multidisciplinary Pre-Conference: Day 1 – *separate registration required*

Eastern Time	Event
10:00 AM – 10:05 AM ET	DAY ONE - OPENING REMARKS Loren D’Angelo, RN-BC, BSN, MSN, CPNP-PC, <i>HTRS 2021 Planning Committee</i>
10:05 AM – 11:30 AM ET	PRE-CONFERENCE SESSION 1: “NEW THERAPIES” <u>Moderators:</u> Loren D’Angelo, RN-BC, BSN, MSN, CPNP-PC, and Caitlin Moncrieff, NP
10:05 AM	DOACS IN THE PEDIATRIC POPULATION Riten Kumar, MD, MSc
10:35 AM	MANAGING INHIBITORS IN THE REALM OF NON-FACTOR THERAPIES James Munn, RN-BC, BS, BSN, MS



Multidisciplinary Pre-Conference: Day 1 – continued

10:55 AM	“GENE THERAPY CLINICAL TRIAL EXPERIENCES IN CARE” Darcy Phelan, NP, MSN
11:20AM	Live Q&A
11:30 AM	DAY ONE PROGRAMMING ENDS Session resumes Thursday, March 11 at 10:00 AM ET

HTRS Scientific Symposium: Day 1

Eastern Time	Event
12:00 PM – 1:00 PM ET	SATELLITE SYMPOSIA: (2) Concurrent Sessions <u>Sanofi Genzyme</u> : "siRNA Technology in Hemophilia" <u>CSL Behring</u> : "On-Demand Bleed Resolution in Hemophilia B With an Extended Half-Life Factor IX Therapy"
1:00 PM – 1:05 PM ET	OPENING REMARKS Jordan Shavit, MD, PhD, <i>HTRS 2021 Planning Committee Chair</i> Ayesha N. Zia, MD, <i>HTRS 2021 Planning Committee Vice Chair</i>
1:05 PM – 2:30 PM ET	SYMPOSIUM SESSION 1 DEBATE: “THE FUTURE OF HEMOPHILIA THERAPEUTICS: SUBSTITUTION OR GENE THERAPY (To GT or not to GT, a smackdown)” <u>Moderators</u> : Jordan Shavit, MD, PhD and Yasmina Abajas, MD <u>Speakers</u> : Denise E. Sabatino, PhD, Michael Callaghan, MD, and Shawn Jobe, MD, PhD
1:05 PM – 1:10 PM	Case Presentation & Introduction to Audience Response System (“ARS”) Jordan Shavit, MD, PhD and Yasmina Abajas, MD
1:10 PM – 1:20 PM	Introduction: “The science behind hemophilia therapeutics” Denise E. Sabatino, PhD



HTRS Scientific Symposium: Day 1 – continued

	SYMPOSIUM SESSION 1 DEBATE: “THE FUTURE OF HEMOPHILIA THERAPEUTICS: SUBSTITUTION OR GENE THERAPY (To GT or not to GT, a smackdown)”
1:20 PM – 1:25 PM	Pre-Debate ARS Vote Jordan Shavit, MD, PhD and Yasmina Abajas, MD
1:25 PM – 1:40 PM	Argument for Substitution Michael Callaghan, MD
1:40 PM – 1:55 PM	Argument for Gene Therapy Shawn Jobe, MD, PhD
1:55 PM – 2:05 PM	Rebuttal for Substitution Michael Callaghan, MD
2:05 PM – 2:15 PM	Rebuttal for Gene Therapy Shawn Jobe, MD, PhD
2:15 PM – 2:25 PM	Questions/Discussion Jordan Shavit, MD, PhD and Yasmina Abajas, MD
2:25 PM – 2:30 PM	Post-Debate ARS Vote Jordan Shavit, MD, PhD and Yasmina Abajas, MD
2:30 PM – 3:30 PM ET	NETWORKING & EXHIBITOR SPEED BREAK



HTRS Scientific Symposium: Day 1 – continued

3:30 PM – 4:30 PM ET	ORAL ABSTRACT PRESENTATIONS: (2) Concurrent Sessions	
	vWF/HEMOPHILIA A Moderators: Christine Kempton, MD, MSc and Joshua Muia, PhD	Novel Mechanisms & Trials Moderators: A. Valance Washington, PhD and Lauren Amos, MD
3:30 PM	“THE IMPORTANCE OF GENETIC TESTING IN DIAGNOSING VON WILLEBRAND’S DISEASE TYPE 2M” Presenter: Radia Ksayer, MD	“PLATELETS FACTOR 4 (PF4) BINDING ENHANCES IN VITRO NEUTROPHIL EXTRACELLULAR TRAPS (NET) CAPTURE OF SARS-COV-2: THERAPEUTIC IMPLICATIONS” Presenter: Maki Ishizuka, MD
3:45 PM	“VON WILLEBRAND FACTOR (VWF) MULTIPLEX ACTIVITY ASSAY DIFFERENTIATION OF LOW VWF/TYPE 1 VON WILLEBRAND DISEASE (VWD) AND VARIANT VWD: ANALYSIS FROM THE COMPARATIVE EFFECTIVENESS IN THE DIAGNOSIS OF VWD” Presenter: Jonathan C. Roberts, MD	“IN VITRO-GROWN MEGAKARYOCYTES (MKS) TAKE UP THE ECTOPIC PROTEIN UROKINASE (UPA) AND THE RESULTING PLATELETS (PLTS) CAN RELEASE THE UPA AT SITES OF VASCULAR INJURY” Presenter: Sergei V. Zaitsev, PhD
4:00 PM	Non-CME Presentation: “BROAD PATIENT ELIGIBILITY AND LONG-TERM TOLERABILITY IN THE FIRST-IN-HUMAN GENE THERAPY STUDY OF AAVHU37.HFVIIIICO IN SEVERE HEMOPHILIA A” Presenter: Francesca Ferrante, MD	“BLEEDING DIATHESIS IN MICE LACKING JAK2 IN PLATELETS” Presenters: Nathan Eaton, BSc
4:15 PM	Non-CME Presentation: “REAL-WORLD DATA FROM A US CLAIMS DATABASE AMONG PATIENTS WITH HEMOPHILIA A TREATED WITH RECOMBINANT FVIII FC FUSION PROTEIN” Presenter: Amanda Wilson, MPH, PhD	“A RANDOMIZED, PRAGMATIC TRIAL TO ASSESS A PEDIATRIC REAL-TIME RISK PREDICTION MODEL FOR THROMBOTIC EVENTS” Presenters: Shannon C. Walker, MD
4:30 PM - 5:30 PM ET	OPEN NETWORKING	
5:30 PM - 6:30 PM ET	SATELLITE SYMPOSIA: (1) Session Takeda: “ADVATE® [Antihemophilic Factor (Recombinant)] Clinical Presentation”	
6:30 PM ET	DAY ONE PROGRAMMING ENDS General Session resumes Thursday, March 11 at 12:00 PM ET	



THURSDAY, MARCH 11, 2021

Multidisciplinary Pre-Conference: Day 2 – separate registration required

Eastern Time	Event
10:00 AM – 10:05 AM ET	DAY TWO - OPENING REMARKS Loren D’Angelo, RN-BC, BSN, MSN, CPNP-PC, <i>HTRS 2021 Planning Committee</i>
10:05 AM – 11:30 AM ET	PRE-CONFERENCE SESSION 2: INCLUSIVE CARE <u>Moderators:</u> Mary Lesh, PNP, MSN and Caitlin Moncrieff, NP
10:05 AM	TRAUMA INFORMED CARE FOR HEMATOLOGY PROVIDERS Amanda Stahl, LICSW
10:35 AM	HEMATOLOGIC CONSIDERATIONS IN THE CARE OF TRANSGENDER PATIENTS Meredith Russel, PNP, MSN
11:15 AM	Live Q&A
11:30 AM ET	<i>HTRS 2021 Multidisciplinary Pre-conference Ends</i>

HTRS Scientific Symposium: Day 2

Eastern Time	Event
12:00 PM – 1:00 PM ET	SATELLITE SYMPOSIA: (2) CONCURRENT SESSIONS <u>Novo Nordisk:</u> “A rFVIIa with over 30 years of experience with treating hemophilia and other rare bleeding disorders” <u>Bayer:</u> “Patient focused prophylaxis management for patients with hemophilia: a case-based discussion”
1:00 PM – 1:05 PM ET	OPENING REMARKS Gowthami Arepally, MD, <i>HTRS 2021 Planning Committee – Abstract Co-Chair</i> Alan Mast, MD, PhD, <i>HTRS 2021 Planning Committee – Abstract Co-Chair</i>



HTRS Scientific Symposium: Day 2 – continued

1:05 PM – 2:10 PM ET	SYMPOSIUM SCIENTIFIC SESSION 2: STATE-OF-THE-ART LECTURE: “COVID-19: THROMBOSIS AND CLINICAL CONSIDERATIONS” <u>Moderator:</u> Jordan A. Shavit, MD, PhD and Andrea Obi, MD, <i>Co-moderator</i> <u>Speakers:</u> Roger Lewis, MD, Robert Campbell, PhD, and Hanny Al-Samkari, MD	
2:10 PM - 3:10 PM ET	EXCLUSIVE SATELLITE SYMPOSIUM GENENTECH: “SubQ Prophylaxis for Hemophilia A: 3 Experts Discuss the Latest Data From the Pivotal Trials”	
3:10 PM – 4:10 PM ET	ORAL ABSTRACT PRESENTATIONS: (2) Concurrent Sessions	
	THROMBOSIS Moderators: Hervé Falet, PhD and Rachel Rosovsky, MD	HEMOPHILIA B Moderators: Lacramioara Ivanciu, PhD and Janice Staber, MD
3:10 PM	“INVESTIGATING THE REGULATION OF RAP1-INTEGRIN SIGNALING PATHWAY USING THE IMMKCL MEGAKARYOCYTE MODEL” Presenter: Ankita Dhenge, PhD	“AMT-060 GENE THERAPY IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B CONFIRM STABLE FIX EXPRESSION AND SUSTAINED REDUCTIONS IN BLEEDING AND FACTOR IX USE FOR UP TO 5 YEARS” Presenter: Frank W.G Leebeek, MD, PhD
3:25 PM	“FORMATION OF PROTHROMBINASE ON HUMAN ENDOTHELIAL CELLS” Presenter: Clay T. Cohen, MD	“ETRANACOGENE DEZAPARVOVEC (AAV5-PADUA HFIX VARIANT), AN ENHANCED VECTOR FOR GENE TRANSFER IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B: TWO YEAR DATA FROM A PHASE 2B TRIAL” Presenter: Annette von Drygalski, MD, PharmD
3:40 PM	“HEMATOLOGIC ABNORMALITIES AND VENOUS THROMBOPROPHYLAXIS IN MIS-C: DATA FROM A MULTI-DISCIPLINARY WORKING GROUP AT A PEDIATRIC TERTIARY CARE HOSPITAL” Presenter: Lynn M. Malec, MD, MSc	“EFFICACY AND SAFETY OF ETRANACOGENE DEZAPARVOVEC IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B: FIRST DATA FROM THE PHASE 3 HOPE-B GENE THERAPY TRIAL” Presenter: Steven W. Pipe, MD
3:55 PM	“RISK OF VENOUS THROMBOEMBOLISM IN PEDIATRIC HOSPITALIZED PATIENTS UNDERGOING NON-CARDIAC SURGERY, A REPORT FROM THE CHILDREN'S HOSPITAL-ACQUIRED THROMBOSIS (CHAT) CONSORTIUM” Presenter: Elizabeth T. Stephens, DO	Non-CME Presentation: “CLEARANCE OF FIDANACOGENE ELAPARVOVEC VECTOR DNA IN PATIENTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B (HB)” Presenter: Patrick F. Fogarty, MD



HTRS Scientific Symposium: Day 2 – continued

4:10 PM – 4:15 PM ET	TRANSITION TO REMO
4:15 PM – 5:15 PM ET	<p>POSTER PRESENTATIONS + SPEED SESSIONS</p> <ul style="list-style-type: none"> • “A Survey of Anti-platelet and Anticoagulant Use in Persons with Hemophilia” Presenter: Maissaa Janbain, MD, MSCR • “Bleeding Disorder Referrals to Hematology Clinic: A Single Institution Experience” Presenter: Zuri Hudson, DO • “Catastrophic Thrombotic Syndrome in Systemic Lupus Erythematosus without Antiphospholipid Antibodies” Presenter: Krystal J. Park, MD • “Drive-through Anticoagulation Clinic During COVID-19 Pandemic” Presenter: Vilmarie Rodriguez, MD • “ECMO Blood Product Utilization: The First 24 Hours” Presenter: Anusha Chidharla, MD • “Eculizumab Treatment for Refractory Thrombosis in Antiphospholipid Syndrome” Presenter: Habiba Hussain, MD • “Efficacy and Safety of Damoctocog Alfa Pegol is Sustained for up to ≥6 Years of Observation in Patients Aged 12– < 18 years at Enrollment into PROTECT VIII” Presenter: Jonathan Ducore, MD, MPH • “Gastrointestinal Bleeding in Patients with von Willebrand Disease: Treatments and Outcomes” Presenter: Jonathan C. Roberts, MD • “Implementation and Analysis of a Venous Thromboembolism Prophylaxis Algorithm in Hospitalized Pediatric Patients” Presenter: Nora M. Gibson, MD • “NHF Builds a Community-Driven National Research Agenda for Inherited Bleeding Disorders” Presenter: Michelle L. Witkop, DNP, FNP-BC • “Perceptions about the use and efficacy of Extended Half-Life (EHL) factor products in persons with hemophilia: A national survey of providers from Hemophilia Treatment Centers in the United States” Presenter: Neeraja Swaminathan, MBBS • “Single Center Experience of Bleeding Evaluation in Hemophilia Carriers using ISTH-BAT” Presenter: Maria Carter Febres, MD • “Successful Implementation of a Pediatric Bleeding Assessment Tool in the Electronic Medical Record in an Academic Clinical Setting” Presenter: Kelly Bajorek, BS • “Surgical Procedures in Patients with Hemophilia: Multistakeholder Perspectives From 2018 Roundtables” Presenter: Miguel A. Escobar, MD • “Telegenetic Counseling for Female My Life, Our Future Participants” Presenter: Maria E. Santaella, RN-BC, MSN, CPHON • “Thromboprophylaxis to Improve Outcomes in COVID-19: An Indian Expert Consensus” Presenter: Agam Vora, MD • “Unprovoked extensive deep vein thrombosis in a pediatric patient with sickle cell disease and duplicated inferior vena cava” Presenter: Ramya Ramakrishnan, MD • “Venous Thromboembolic Disease in Children Associated with COVID-19” Presenter: Shalu Narang, MD MPH • Non-CME Presentation: “Single-dose Pharmacokinetics, Efficacy, and Safety of Fibrinogen Concentrate for On-Demand Treatment of Acute Bleeding and Surgical Prophylaxis in Patients with Congenital Fibrinogen Deficiency” Presenter: Bruce Schwartz, PhD



HTRS Scientific Symposium: Day 2 – continued

5:15 PM – 6:15 PM ET	OPEN NETWORKING
6:15 PM – 7:15 PM ET	<p>SATELLITE SYMPOSIA: 2 Concurrent Sessions</p> <p><u>Takeda/PER (CME):</u> “Putting the Patient First: Individualized Strategies for the Treatment and Management of von Willebrand Disease”</p> <p><u>Novo Nordisk:</u> “Double Feature: Obesity in Hemophilia and a Treatment Option for Hemophilia A”</p>
7:15 PM	<p><i>DAY TWO PROGRAMMING ENDS</i></p> <p><i>General Session resumes Friday, March 12 at 12:00 PM ET</i></p>

FRIDAY, MARCH 12, 2021

HTRS Scientific Symposium: Day 3

Eastern Time	Event
12:00 PM – 1:00 PM ET	<p>SATELLITE SYMPOSIA: (2) Concurrent Sessions</p> <p><u>Sanofi Genzyme:</u> "A Breakthrough in aTTP Treatment: Now recommended by the ISTH Guidelines"</p> <p><u>Alnylam Pharmaceuticals:</u> Introduction to GIVLAARI® (givosiran) for the Treatment of Adults with Acute Hepatic Porphyria - Featuring 18-month data from the ENVISION Open-Label Extension (OLE) Study</p>
1:00 PM – 1:05 PM ET	<p>OPENING REMARKS</p> <p>Jordan Shavit, MD, PhD, <i>HTRS 2021 Planning Committee Chair</i></p> <p>Ayesha N. Zia, MD, <i>HTRS 2021 Planning Committee Vice Chair</i></p>
1:05 PM – 2:10 PM ET	<p>SCIENTIFIC SESSION 3: “BENCH, CLINIC, AND EVERYTHING IN-BETWEEN” (3) Concurrent Sessions</p> <p>Session 3-A: “Platelets”</p> <p><u>Moderators:</u> Pavel Davizon-Castillo, MD and Jorge Di Paola, MD, Co-moderator</p> <p><u>Speakers:</u> Rachael Grace, MD, Jeanne Hendrickson, MD, Kellie Machlus, PhD</p>



HTRS Scientific Symposium: Day 3 – continued

	<p>Session 3-B: “Sickle Cell-Associated Thrombosis” <u>Moderators:</u> Courtney Thornburg, MD and Deirdre S. Nolfi-Donagan, MD, <i>Co-moderator</i></p> <p><u>Speakers:</u> Morey Blinder, MD, Erica Sparkenbaugh, PhD, Huanghe Yang, PhD</p> <p>Session 3-C: “Post-VTE Functional Syndromes” <u>Moderators:</u> Ayesha N. Zia, MD and Marisol Betensky, MD, MPH, <i>Co-moderator</i></p> <p><u>Speakers:</u> Susan Kahn, MD, MSc, FRCPC, ABIM, Farouc Jaffer, MD, PhD, Peter Henke, MD</p>
2:10 PM – 2:20 PM ET	TRANSITION TO REMO
2:20 PM – 3:20 PM ET	NETWORKING & EXHIBITOR SPEED BREAK
3:20 PM – 4:20 PM ET	<p>POSTER PRESENTATIONS AND SPEED SESSIONS</p> <ul style="list-style-type: none"> • “ATHN 16: Safety of Coagulation Factor VIIa (recombinant)-jncw for the Treatment of Bleeding Events in Patients with Hemophilia A or B with Inhibitors with or without Prophylactic Treatment” Presenter: Michael Callaghan • “Clinical Study to Investigate the Efficacy and Safety of a Von Willebrand Factor FVIII Concentrate (VWF/FVIII) during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)” Presenter: Robert Sidonio • “Community Voices in Research (CVR); A Patient-Centric Approach Moving the Future of Inherited Bleeding Disorders Forward” Presenter: Rosaura Vidal • “Development & Testing of an Asynchronous Hemophilia Learning Module” Presenter: Tiffany Lucas • “Evaluation of the hemostatic efficacy of eptacog beta (recombinant factor VIIa) for the treatment of bleeding in pediatric subjects (< 12 years) with hemophilia A or B with inhibitors in PERSEPT 2” Presenter: Steven Pipe • “Examination and Validation of a Patient-Centric Joint Metric: “PROBLEM JOINT”; Empirical Evidence from the CHES US Dataset” Presenter: Tom Burke • “How to Reduce Hypercoagulability Testing in the Inpatient Setting? A Quality Improvement Initiative” Presenter: James Hall • HTRS Student Research Award: “Development of an immunoproteomic pipeline for the characterization of anti-FVIII molecular and cellular repertoires in hemophilia A inhibitor patients” Presenter: Robert Chen • HTRS Student Research Award: “Risk Factors for Non-Variceal Hemorrhage in Patients with Chronic Liver Disease” Presenter: Preethi Kesavan • “Magnetically powered microwheel thrombolysis of occlusive thrombi in zebrafish” Presenter: Jordan Shavit • “Management of Recurrent Disease in Acquired Hemophilia A” Presenter: Aaron Boothby • “Passive Infusion Logging System (PILS): A pilot” Presenter: Maria Santaella



HTRS Scientific Symposium: Day 3 – continued

	<ul style="list-style-type: none"> • HTRS Student Research Award: “Reduced Health-Related Quality of Life is Associated with Depression and Cognitive Impairment Among Survivors of Thrombotic Thrombocytopenic Purpura” Presenter: Sruthi Selvakumar • “SHORT-TERM OUTCOME of NEONATAL VENOUS THROMBOEMBOLISM for ANTICOAGULATED and OBSERVED PATIENTS” Presenter: Kisha Beg • “The Safety of Eptacog Beta in Hemophilia Patients with Inhibitors in Adult, Pediatric, and Surgical Settings” Presenter: Miguel Escobar • “The value of immature platelet fraction of platelet apheresis products in prediction of platelet transfusion response in thrombocytopenic cancer patients” Presenter: Ekrem Turk • “Warfarin-induced skin necrosis in patients with protein C and S hereditary deficiency. Systematic review” Presenter: Rafael Pichardo-Rodriguez • Non-CME Presentation: “Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the ENVISION Open Label Extension” Presenter: David Rees • Non-CME Presentation: Clinical Outcomes in Patients with Acute Hepatic Porphyria Treated with Givosiran Who Stopped Hemin Prophylaxis at Study Entry: A Post-hoc Analysis from the Phase 3 ENVISION Study Through Month 12” Presenter: Herbert Bonkovsky
4:20 PM - 4:30 PM ET	INTRODUCTION TO CLOSING EXTRAVAGANZA
4:30 PM - 5:30 PM ET	CLOSING EXTRAVAGANZA NETWORKING & THE FIRST-EVER “HTRS TALENT SHOW”
5:30 PM ET	<p><i>HTRS 2021 SCIENTIFIC SYMPOSIUM PROGRAMMING ENDS</i></p> <p>Mark your calendars for the next HTRS Scientific Symposium:</p> <p>March 10 - 12, 2023 Renaissance Orlando at SeaWorld Orlando, FL</p>